Cargando…

Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

AIMS: At present, an increasing number of studies are trying to determine whether dapagliflozin has a significant effect on the occurrence and development of atherosclerosis in patients with type 2 diabetes mellitus (T2DM), but there is no consensus. In addition, the former meta-analyses, relying on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Qian-Long, Zheng, Ting, Li, Sheng-Zhen, Chen, Jin-An, Xie, Zi-Chun, Lai, Jian-Mei, Zeng, Ji-Yuan, Lin, Jin-Ting, Huang, Jia-Shuan, Lin, Min-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908556/ https://www.ncbi.nlm.nih.gov/pubmed/35272683 http://dx.doi.org/10.1186/s13098-022-00810-3

Ejemplares similares

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Li, Feng-fei, et al.
Publicado: (2016)

Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
por: Wang, Ji-Yu, et al.
Publicado: (2019)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(−/−) Mice
por: Leng, Weiling, et al.
Publicado: (2016)

Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients
por: Zeng, Jianping, et al.
Publicado: (2021)

Contribution of TLR4 signaling in intermittent hypoxia-mediated atherosclerosis progression
por: Zeng, Xianqin, et al.
Publicado: (2018)

Linezolid-Induced Pancytopenia in Patients Using Dapagliflozin: A Case Series
por: Li, Meng Mei, et al.
Publicado: (2022)

The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies
por: Ma, Jian, et al.
Publicado: (2021)

The protective effects and underlying mechanisms of dapagliflozin on diabetes-induced testicular dysfunction
por: Luo, Zhi-Chao, et al.
Publicado: (2022)

Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
por: Jin, Ze-Jun, et al.
Publicado: (2023)

Corrigendum: Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria
por: Wang, Ji-Yu, et al.
Publicado: (2020)

Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction
por: Xuan, Mei Ying, et al.
Publicado: (2022)

Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model
por: Yang, Mei, et al.
Publicado: (2020)

Novel Gold Dendritic Nanoforests Combined with Titanium Nitride for Visible-Light-Enhanced Chemical Degradation
por: Shiao, Ming-Hua, et al.
Publicado: (2018)

Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region
por: Liao, Chia-Te, et al.
Publicado: (2021)

Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation‐Induced Myocardial Dysfunction
por: Lin, Yu‐Wen, et al.
Publicado: (2021)

Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition
por: Chen, Weixiang, et al.
Publicado: (2023)

Spices and Atherosclerosis
por: Tsui, Pi-Fen, et al.
Publicado: (2018)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

The emerging role of pyroptosis-related inflammasome pathway in atherosclerosis
por: Xu, Xiao-Dan, et al.
Publicado: (2022)

Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
por: Luo, Ting, et al.
Publicado: (2023)

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
por: Tang, Yi, et al.
Publicado: (2022)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Application of Balloon AngioplaSty with the dIstal protection of Stent Retriever (BASIS) technique for acute intracranial artery atherosclerosis-related occlusion
por: Yi, Ting-yu, et al.
Publicado: (2022)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Rosiglitazone attenuates atherosclerosis and increases high-density lipoprotein function in atherosclerotic rabbits
por: LI, CHEN, et al.
Publicado: (2015)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Role of PI3K in the Progression and Regression of Atherosclerosis
por: Zhao, Yunyun, et al.
Publicado: (2021)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
por: Wu, De-long, et al.
Publicado: (2022)

Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats
por: Yang, Xudong, et al.
Publicado: (2023)

Network pharmacological analysis of corosolic acid reveals P4HA2 inhibits hepatocellular carcinoma progression
por: Tang, Fei-Feng, et al.
Publicado: (2023)

SOX30 methylation correlates with disease progression in patients with chronic myeloid leukemia
por: Zhang, Ting-Juan, et al.
Publicado: (2019)

Pyroptosis in the Initiation and Progression of Atherosclerosis
por: Qian, Zhengtao, et al.
Publicado: (2021)

Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation
por: Hu, Jiaxin, et al.
Publicado: (2023)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy
por: Bai, Zhenyu, et al.
Publicado: (2022)

Dapagliflozin-affected endothelial dysfunction and altered gut microbiota in mice with heart failure
por: Bao, Nandi, et al.
Publicado: (2023)

The involving progress of MSCs based therapy in atherosclerosis
por: Lin, Ying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_40j12qqf6mlpvk4vrida7kvchl